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ABSTRACT 
 
ABC transporters export clinically-relevant drugs and their over-expression causes multidrug resistance. In 
order to knock-down ABC transporters, ABCC1 and ABCC2, 13 shRNAs were developed. Four shRNA 
candidates were tested in vivo using self-complementary adeno-associated virus serotype 8. A strong, specific 
knock-down of Abbc2 was observed in mice liver, but at the cost of toxicity caused by oversaturation of the 
RNAi machinery due to high shRNA expression. Subsequent generation of artificial miRNAs showed better 
efficacy profile. These results demonstrate the feasibility of knocking down Abbc2 via AAV-delivered 
shRNAs to the liver, and encourage the use of miRNA in further therapeutics development.  
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INTRODUCTION 
 
Hepatocellular carcinoma (HCC) is the fifth most common 
cause of cancer worldwide, with about 750,000 patients 
reported globally each year (International Agency for 
Research on Cancer, website: http://globocan.iarc.fr). Poor 
survival of HCC patients has several causes, frequently 
including resistance to chemotherapy. Many ATP-binding 
cassette (ABC) transporter family members can decrease 
the intracellular concentration of toxic compounds (Cole et 
al, 1994; Hopper-Borge et al, 2004; Tian et al, 2006; 
Hopper-Borge et al, 2009; Lagas et al, 2009). These 
transmembrane pumps are over-expressed in tumor cells, 
hence causing the multidrug resistance phenotype. ABCB1 
and ABCC3 have been shown to be up-regulated in HCC 
(Grude et al, 2002; Mizukoshi et al, 2008) and the up-
regulation of ABCC1 has been associated with a more 
aggressive HCC phenotype (Vander et al, 2008). Thus far 
ABCB1 inhibitors have failed to show benefit during 
clinical trials, but more are being tested (Kuppens et al, 
2007). Decreasing the expression of other ABC 
transporters is a desirable alternative as it could potentially 
reverse the multidrug resistance phenotype. 
 
RNA interference (RNAi) is an attractive approach to 
achieve this goal, as it would allow combinatorial, 
possibly patient-tailored targeting of ABC transporters. 
RNAi is a naturally-occurring post-transcriptional gene 
silencing mechanism, which can induce sequence-
specific degradation of a messenger RNA (mRNA), thus 435 
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reducing gene expression. RNAi can be induced by 
synthetic small interfering RNAs (siRNAs), or by 
intracellular expression of short hairpin RNAs (shRNAs) 
and artificial microRNAs (miRNAs). shRNAs and 
miRNAs are processed by Dicer into siRNAs, which are 
loaded onto the RNA-induced silencing complex (RISC), 
where they mediate sequence-specific mRNA 
recognition, ultimately causing its degradation. In vivo 
siRNA-mediated knock-down of Abbc1 has been 
demonstrated after intratumoral siRNA injection 
followed by in situ electroporation of the tumor; this led 
to a reduction in tumor weight in response to epirubicin 
(Wu et al, 2011). In addition, Abbc2 was inhibited in 
vitro and in vivo by plasmid-, adenovirus- and lentivirus-
delivered shRNAs, which respectively resulted in 
reversed cisplatin and paclitaxel resistance (Materna et 
al, 2006), decreased bilirubin transport (Narvaiza et al, 
2006), and reduced growth of cisplatin-treated tumors 
(Xie et al, 2008). Despite these findings, the major 
problem of RNAi applications still lies in sustained and 
tissue-specific delivery of the effector molecules in vivo. 
Recombinant adeno-associated virus (AAV) has emerged 
as the vector of choice for gene therapy and for RNAi-
mediated therapy, as it yields long-term, tissue-specific 
expression without any apparent pathogenicity (Daya et 
al, 2008). In the current study we assessed the feasibility 
of  in vivo AAV-mediated knock-down of two murine 
endogenous ABC transporters: ABCC1 and ABCC2. 
Initially, we verified the knock-down activity of 13 
shRNA constructs and selected two candidates targeting 
Abbc2 for further in vivo testing. A single injection of 
self-complementary AAV8 (scAAV8) carrying shAbcc2 
resulted in efficient Abbc2 knock-down in murine liver. 
Concomitant signs of toxicity including elevated 
transaminases were attributed to high levels of shRNAs 
being processed into siRNAs, causing oversaturation of 
the RNAi machinery. Nevertheless, subsequent 
translocation of the validated shRNA sequences into a 
miRNA scaffold offers the perspective of safe AAV-
mediated in vivo knock-down. 
 
MATERIALS AND METHODS 
 
DNA constructs 
Six shRNA constructs targeting murine Abbc1 and seven 
targeting murine Abbc2, and control shRNAs targeting 
eGFP (shGFP) and Luciferase (shLuc) and a scramble 
sequence (shScr) were made by annealing of 
complementary oligonucleotides and ligating them into the 
pSuper vector containing the H1 Pol III promoter 
(OligoEngine, Seattle, WA). The sequence for constructing 
the negative control hairpin shScr has been described 
previously (Doege et al, 2008). The sequences of 
oligonucleotides used in this study are listed in Table 1. 
Luciferase reporters Luc-Abbc11/17 and Abbc22/28 were 
made by cloning of Abbc1/2 sequences behind renilla 
luciferase in the siCheck vector (Promega, Madison, WI). 
 
For cloning in the AAV backbone, the H1-shRNA 
expression cassettes were subcloned in pCR-Blunt II-
TOPO vector (Invitrogen, Carlsbad, CA), and then ligated 
in the pVD287 vector. pVD287 contains the egfp gene 
under the control of the liver-specific LP-1 promoter and 
generates scAAV due to a mutation in one terminal repeat 
(McCarty et al, 2003).  
 
Cell culture and transfections 
Human embryonic kidney (HEK) 293T and murine 
hepatoma (Hepa1-6) cell lines were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM, 
Invitrogen) containing 10% (v/v) fetal calf serum, 
100U/ml penicillin and 100U/ml streptomycin, at 37
oC 
and 5% (v/v) CO2.  Cells were plated in 6-, 24- or 96-well 
plates one day prior to transfection. Transfections were 
performed with Lipofectamine 2000 reagent (Invitrogen) 
according to the manufacturer’s instructions. For the 
interferon response experiment we transfected 2μg of a 
synthetic analog of dsRNA, polyinosinic:polycytidylic 
acid (poly I:C), as a positive control. 
 
Luciferase assays 
For luciferase assays, cells were co-transfected with 10ng 
Luc-Abbc reporter that contains both firefly and renilla 
luciferase genes, and 0, 0.5, 2.5, 10 or 50ng of the 
corresponding shAbcc expression construct. Transfected 
cells were assayed at 48hr post-transfection and firefly and 
renilla luciferase were measured with the Dual-Luciferase 
Reporter Assay System (Promega). Relative luciferase 
activity was calculated as the ratio between the renilla and 
firefly luciferase activities, and transfection with shScr 
was set at 100%. Data are represented as mean values ±SD 
from a representative experiment conducted with three 
technical replicates. 
 
RNA isolation, quantitative RT-PCR (RT-qPCR), 
siRNA and miRNA Taqman assays 
For  in vitro experiments, total RNA was isolated from 
cells 18hr or 72hr post-transfection using the Nucleospin 
kit (Clontech, Mountain View, CA). For in vivo 
experiments, total RNA was isolated from frozen liver 
sections at two weeks post-injection (p.i.) using Trizol 
(Invitrogen) according to the manufacturer’s protocol. 
DNAse-treatment and RT-qPCR were performed as 
described previously (Koornneef et al, 2011) and data are 
represented as mean values ±SD from a representative 
experiment conducted with three technical replicates. 
siRNA and miRNA expression was quantified with 
custom-made siRNA assays or miRNA-specific Taqman 
assays (Applied Biosystems, Foster City, CA) according to 
manufacturer’s instructions. 
 
AAV vector production and in vivo experiments 
Self-complementary AAV8 vectors were produced and 
purified as previously described (Zolotukhin et al, 1999; 
Gao et al, 2002; Koornneef et al, 2011) with an added 
fractionation step yielding higher virus concentration. 
Final concentration was determined by qPCR with LP1 
primers. All animal experiments were conducted 
according to the guidelines of the local animal welfare 
committee. Six-to-eight-week-old male C57BL/6 mice 
received 2.2x10
11gc AAV-shScr, 2.6-3x10
12gc AAV-
shAbcc22 or -shAbcc28 per animal intravenously via the 
tail vein. Heparinized blood samples were taken by retro-
orbital bleeding at 1 and 2 weeks p.i. for plasma analysis. 
Mice were sacrificed on day 15 p.i. and livers were 
examined for Abbc1 and Abbc2 knock-down. Plasma levels436 
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Table 1. Oligonucleotide sequences used in this study. mmu-Abcc1 (NM_008576), mmu-Abcc2 (NM_013806), luc and gfp 
sequences in the shRNA oligos are in bold. 
 
Name Sequence (5'-3')
shAbcc11-f GATCCCCGATGACACACCTCAACAAATTCAAGAGATTTGTTGAGGTGTGTCATCTTTTTA Abcc1 207-225
shAbcc11-r TCGAGAAAAAGATGACACACCTCAACAAATCTCTTGAATTTGTTGAGGTGTGTCATCGGG
shAbcc12-f GATCCCCTTACTACAAGGCAGTTATGTTCAAGAGACATAACTGCCTTGTAGTAATTTTTA Abcc1 2214-2232
shAbcc12-r TCGAGAAAAATTACTACAAGGCAGTTATGTCTCTTGAACATAACTGCCTTGTAGTAAGGG
shAbcc15-f GATCCCCTCTACTTCTTCTATCTCTCTTCAAGAGAGAGAGATAGAAGAAGTAGATTTTTA Abcc1 169-182
shAbcc15-r TCGAGAAAAATCTACTTCTTCTATCTCTCTCTCTTGAAGAGAGATAGAAGAAGTAGAGGG
shAbcc16-f GATCCCCTGTTCAATATCTTGCGCTTTTCAAGAGAAAGCGCAAGATATTGAACATTTTTA Abcc1 1175-1793
shAbcc16-r TCGAGAAAAATGTTCAATATCTTGCGCTTTCTCTTGAAAAGCGCAAGATATTGAACAGGG
shAbcc17-f GATCCCCGAAGCTAATGGAAGCAGACTTCAAGAGAGTCTGCTTCCATTAGCTTCTTTTTA Abcc1 2832-2850
shAbcc17-r TCGAGAAAAAGAAGCTAATGGAAGCAGACTCTCTTGAAGTCTGCTTCCATTAGCTTCGGG
shAbcc18-f GATCCCCCCTGGACCTGCTATACAATTTCAAGAGAATTGTATAGCAGGTCCAGGTTTTTA Abcc1 3147-3165
shAbcc18-r TCGAGAAAAACCTGGACCTGCTATACAATTCTCTTGAAATTGTATAGCAGGTCCAGGGGG
shAbcc22-f GATCCCCCTTGGCTAGGAGGCAGTACTTCAAGAGAGTACTGCCTCCTAGCCAAGTTTTTA Abcc2 1221-1239
shAbcc22-r TCGAGAAAAACTTGGCTAGGAGGCAGTACTCTCTTGAAGTACTGCCTCCTAGCCAAGGGG
shAbcc23-f GATCCCCCCATGTTCTGGATTCTCTCTTCAAGAGAGAGAGAATCCAGAACATGGTTTTTA Abcc2 395-413
shAbcc23-r TCGAGAAAAACCATGTTCTGGATTCTCTCTCTCTTGAAGAGAGAATCCAGAACATGGGGG
shAbcc24-f GATCCCCTGACCAACTACTACACTTTTCAAGAGAAAGTGTAGTAGTTGGTCATTTTTA Abcc2 1295-1313
shAbcc24-r TCGAGAAAAATGACCAACTACTACACTTTCTCTTGAAAAGTGTAGTAGTTGGTCAGGG
shAbcc25-f GATCCCCCATCTATATTCTAGACGACTTCAAGAGAGTCGTCTAGAATATAGATGTTTTTA Abcc2 2334-2352
shAbcc25-r TCGAGAAAAACATCTATATTCTAGACGACTCTCTTGAAGTCGTCTAGAATATAGATGGGG
shAbcc26-f GATCCCCTTACTTGTAACATCAAGAGTTCAAGAGACTCTTGATGTTACAAGTAATTTTTA Abcc2 3953-3971
shAbcc26-r TCGAGAAAAATTACTTGTAACATCAAGAGTCTCTTGAACTCTTGATGTTACAAGTAAGGG
shAbcc27-f GATCCCCATACTGGACAAGCCACAATTTCAAGAGAATTGTGGCTTGTCCAGTATTTTTTA Abcc2 266-284
shAbcc27-r TCGAGAAAAAATACTGGACAAGCCACAATTCTCTTGAAATTGTGGCTTGTCCAGTATGGG
shAbcc28-f GATCCCCTCTCTACCTATGCACTTGGTTCAAGAGACCAAGTGCATAGGTAGAGATTTTTA Abcc2 312-330
shAbcc28-r TCGAGAAAAATCTCTACCTATGCACTTGGTCTCTTGAACCAAGTGCATAGGTAGAGAGGG
shScr-f GATCCCCGATCGAATGTGTACTTCGATTCCAAGAGATCGAAGTACACATTCGATCTTTTTGCATGCC Doege et al. 2008
shScr-r TCGAGGCATGCAAAAAGATCGAATGTGTACTTCGATCTCTTGGAATCGAAGTACACATTCGATCGGG
shGFP-f GATCCCCAGCTGGAGTACAACTACAACCTTCCTGTCAGTTGTAGTTGTACTCCAGCTTTTTGCATGCC eGFP
shGFP-r TCGAGGCATGCAAAAAGCTGGAGTACAACTACAACTGACAGGAAGGTTGTAGTTGTACTCCAGCTGGG
shLuc-M-f GATCCCCCTGCCCTGCTGGTGCCCACACTTCCAAGAGAGTGTGGGCACCAGCAGGGCAGTTTTTGCATGCC Luc
shLuc-M-r TCGAGGCATGCAAAAACTGCCCTGCTGGTGCCCACACTCTCTTGGAAGTGTGGGCACCAGCAGGGCAGGGG
Luc-Abcc11-f TCGAGTCTCTCTCGCCATGACCGGGGCTACATCCAGATGACACACCTCAACAAAACCAAAACTGCCTTAGGATT
CTTTCTGC
Abcc11
Luc-Abcc11-r GGCCGCAGAAAGAATCCTAAGGCAGTTTTGGTTTTGTTGAGGTGTGTCATCTGGATGTAGCCCCGGTCATGGCG
AGAGAGAC
Luc-Abcc17-f TCGAGGCAGAAGGCTGGAGCTAAGGAGGAGACGTGGAAGCTAATGGAAGCAGACAAGGCCCAGACAGGGCAGGT
GCAGCTGC
Abcc17
Luc-Abcc17-r GGCCGCAGCTGCACCTGCCCTGTCTGGGCCTTGTCTGCTTCCATTAGCTTCCACGTCTCCTCCTTAGCTCCAGC
CTTCTGCC
Luc-Abcc22-f TCGAGTATATAAGAAGGCACTAACCCTATCTAACTTGGCTAGGAGGCAGTACACGATTGGAGAGACGGTGAACT
TGATGC
Abcc22
Luc-Abcc22-r GGCCGCATCAAGTTCACCGTCTCTCCAATCGTGTACTGCCTCCTAGCCAAGTTAGATAGGGTTAGTGCCTTCTT
ATATAC
Luc-Abcc28-f TCGAGACCTCTCACAGAAGATACTGGACAAGCCACAATTCCTCCTGTTAAATATACAAATCCAATTCTCTACCT
ATGCACTTGGCTCCTGGTGTTGGTGGCAGGC
Abcc28
Luc-Abcc28-r GGCCGCCTGCCACCAACACCAGGAGCCAAGTGCATAGGTAGAGAATTGGATTTGTATATTTAACAGGAGGAATT
GTGGCTTGTCCAGTATCTTCTGTGAGAGGTC
Abcc1-f GAGTCAAAGCCGGTGGAAAAT Abcc1 qRT-PCR
Abcc1-r TTAGCTCCAGCCTTCTGCAGTT
Abcc2-f TGAAAAACAGAATGGGACCGA Abcc2 qRT-PCR
Abcc2-r TTGGATGCATTTCTGCAAGC
Actin-f ACGGCCAGGTCATCACTATTG βactin qRT-PCR
Actin-r CAAGAAGGAAGGCTGGAAAAGA
Gapdh-f ACATGTTCCAGTATGACTCCACTCA Gapdh qRT-PCR
Gapdh-r GCCTCACCCCATTTGATGTT
Hprt-f AAGACTTGCTCGAGATGTCATGAAG Hprt qRT-PCR
Hprt-r TCCAGCAGGTCAGCAAAGAA
Ifnb1-f CTGCCTTTGCCATCCAAGAG Ifnb1 qRT-PCR
Ifnb1-r ACTGTCTGCTGGTGGAGTTC
Igs56-f TGCACAACCTCCTGGCCTAC Isg56 qRT-PCR
Igs56-r TCGCCAGGCTTCTCTTGCTC
Oas1b-f TGATGTGCTGCCAGCCTATG Oasb1b qRT-PCR
Oas1b-r GATAACTTGCCCTCCTTCCC
Stat1-f GTGAGAGCCAGTCGTTTCAG Stat1 qRT-PCR
Stat1-r GCAGGTTCGGGATTCAACAC
LP1-f CCCTGTTTGCTCCTCCGATAA LP1 qRT-PCR
LP1-r GTCCGTATTTAAGCAGTGGATCCA
Target
 
 
 
 437 
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of alanine aminotransferase (ALT), aspartate amino-
transferase (AST) and total bilirubin were analyzed on 
Modular Analytics P800 analyzer (Roche Diagnostics, 
Basel, Switzerland). Data are represented as mean values 
±SEM (n = 4-5). 
 
RESULTS AND DISCUSSION 
 
Design and validation of shRNAs targeting murine 
Abcc1 and Abcc2 
Six shRNAs were designed against murine Abcc1 mRNA 
(shAbcc11-shAbcc17) (Figure 1A and 1C), and seven 
against murine Abcc2 mRNA (shAbcc22-shAbcc28) 
(Figure 1B and 1D). The ability of these constructs to 
knock-down endogenous Abcc1 and Abcc2 was assessed 
in vitro in Hepa1-6 cells using shGFP and shLuc as 
negative controls. shAbcc11, shAbcc17, and all 7 shAbcc2 
constructs, respectively inhibited endogenous Abcc1 and 
Abcc2 expression by more than 50% (Figure 1E and 1F). 
For each target we selected the 2 most efficient shRNAs: 
shAbcc11 and shAbcc17, shAbcc22 and shAbcc28. 
 
The specificity of Abcc1 and Abcc2 knock-down by these 
4 constructs was tested on luciferase reporters containing 
the Abcc1 or Abcc2 target sequences. For all 4 constructs 
increasing concentrations of the shRNA construct induced 
dose-dependent inhibition of the specific luciferase 
reporter (Figure 1G). These results support the sequence-
specificity of endogenous Abcc1 and Abcc2 knock-down 
by these shRNAs.  
  
siRNA processing was examined in vitro in two cell lines 
and was compared with the siRNA processing of a 
validated active shRNA, shApoB (Koornneef et al, 2011). 
Efficient processing of the shRNA would indicate efficacy 
of the shRNA in vivo. HEK293T and Hepa1-6 cells were 
transfected with increasing amounts of plasmids encoding 
shAbcc22, shAbcc28 and shApoB. All shRNAs expressed 
similar amounts of siRNAs in HEK293T (Figure 1H) and 
Hepa1-6 cells (Figure 1I), indicating that they do not 
suffer from any misprocessing that could impair the 
anticipated in vivo knock-down. 
 
Double-stranded RNA (dsRNA), including siRNAs, can 
induce the interferon response (Sledz et al, 2003). We 
determined that none of the 4 selected shRNAs induced 
expression of marker genes of the interferon response in 
vitro following transfection of Hepa1-6 cells (Figure 2). 
 
In vivo knock-down of Abcc1 and Abcc2 via scAAV-
delivered shRNAs 
C57BL/6 mice were injected with 4x10
12gc/kg scAAV8 
encoding shAbcc11, shAbcc17, shAbcc22, shAbcc28 and 
the shScr and PBS as controls. Animals were sacrificed at 
two weeks p.i. and Abcc1, Abcc2 knock-down and siRNA 
expression in liver was determined, as well as alanine 
aminotransferase (ALT) and aspartate aminotransferase 
(AST) levels in plasma and interferon pathway genes 
expression in white blood cells. Transduction efficiency by 
scAAV8-shAbcc was greater than 90% as determined by 
fluorescence microscopy (data not shown). However, Abcc1 
and Abcc2 mRNA expression was not affected significantly, 
and we could determine only very low levels of siRNA 
(data not shown). We concluded that at this viral dose, these 
shRNAs were not expressed at a level sufficient to show a 
detectable effect. We subsequently narrowed our focus on 
the highly-expressed Abcc2 gene and injected C57 BL/6 
mice with a 10-30 fold higher dose of 1.2-1.3x10
14gc/kg 
AAV-shAbcc22, AAV-shAbcc28, and AAV-shScr and PBS 
as controls. Mice injected with AAV-shAbcc22 and AAV-
shAbcc28 were therefore sacrificed on day-13p.i. in 
agreement with the guidelines of the local animal welfare 
committee as the animals presented some signs of 
physiological stress and one AAV-shAbcc22-injected 
mouse died. Animals from AAV-shScr and PBS groups 
were sacrificed on day-15p.i. Gene expression analysis by 
RT-qPCR in the livers revealed a profound knock-down of 
Abcc2 mRNA up to 83% by shAbcc22 and shAbcc28 
(Figure  3A). Since there were signs of toxicity, we 
determined whether the Abcc2 knock-down was sequence-
specific rather than due to general toxicity. Therefore, the 
expression of the housekeeping genes, β-Actin, 
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and 
hypoxanthine guanine phosphoribosyl transferase (Hprt), 
was determined in RNA isolated from mouse livers. Our 
results indicated no detectable down-regulation of 
expression of the housekeeping genes between the 3 AAV-
injected groups (data not shown), thus indicating the 
sequence-specificity of Abcc2 knock-down by AAV-
shAbcc22 and AAV-Abcc28 in vivo. Further quantification 
of the amount of siAbcc22 and siAbcc28 by Taqman 
revealed a higher number of siRNA in the AAV-shAbcc22-
injected mice than in the AAV-shAbcc28-injected mice 
(Figure 3B). 
 
Interestingly, the mouse injected with AAV-shAbcc22, 
which first showed signs of toxicity and died was indeed 
the one presenting the highest levels of siRNA. While in 
vitro the amount siRNA produced by shAbcc22 and 
shAbcc28 was similar, in vivo there were differences 
between mice injected with the same dose of AAV-
shAbcc22 and AAV-shAbcc28. We conclude that our in 
vitro studies were insufficient predictors of the shRNAs 
processing  in vivo. Nevertheless, in vitro efficacy 
correlated well with in vivo results, which, following 
highly-efficient transduction of hepatocytes with AAV8, 
achieved 83% knock-down of the target mRNA. 
 
During the first week p.i. the mice from the AAV-
shAbcc22 and AAV-shAbcc28 groups did not gain any 
weight, while the AAV-shScr and the PBS groups did 
(data not shown). It appears that the over-expression of 
shAbcc22 and shAbcc28 in vivo resulted in severe 
toxicity. Mice presented several indications of 
physiological stress. Analysis of plasma sampled on day-
8p.i. revealed elevated levels of AST, ALT and total 
bilirubin indicating liver toxicity in the AAV-shAbcc 
groups (Figure 4A). On day-13p.i. one of the AAV-
shAbcc22-injected mice died and subsequently all mice 
from both AAV-shAbcc22 and AAV-shAbcc28 groups 
were sacrificed on the same day. Plasma analysis at two 
weeks p.i. revealed highly-elevated AST and ALT levels 
in the AAV-shScr group (data not shown), and weight loss 
was also observed during the second week p.i., indicating 
a slower onset of the toxicity, most likely due to the lower 
viral dose that was administered to this group. 438 
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Figure 1. shRNAs design and in vitro studies on endogenous Abcc mRNA and Abcc luciferase reporters. Schematic 
representation of Abcc1 and Abcc2 mRNA and target sequences of the shRNAs. (A) shAbcc11, shAbcc12, shAbcc15, 
shAbcc16, shAbcc17, shAbcc18 targeting Abcc1 mRNA (NM_013806.2) and (B) shAbcc22, shAbcc23, shAbcc24, shAbcc25, 
shAbcc26, shAbcc27, shAbcc28 targeting Abcc2 mRNA (NM_008576.2). Predicted stem-loop structure with guide strand in 
red of (C) shAbcc1 and (D) shAbcc2. (E) Endogenous Abcc1 mRNA knock-down by shAbcc1 constructs and (F) endogenous 
Abcc2 mRNA knock-down by shAbcc2 constructs in Hepa1-6 cells (shGFP-treated cells were set at 100%). (G) Luc-Abcc1 
and Luc-Abcc2 knock-down by shAbcc1 and shAbcc2 constructs in HEK293T cells (shScr-treated cells were set at 100%). 
Relative amount of siRNA molecules after transfection of HEK293T (H) and Hepa1-6 cells (I) with shAbcc22, shAbcc28 and 
shApoB (the highest siApoB value was set at 100%). 
 
 
 
A                    B 
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Figure 2. Four interferon pathway genes are not activated by the shAbcc constructs. Expression of interferon pathway genes. (A) 
Interferon beta 1 (Ifnb1), (B) Interferon-stimulated gene 56 (Isg56), (C) 2'-5' oligoadenylate synthetase 1B (Oasb1b), (D) Signal 
transducer and activator of transcription 1 (Stat1). Gene expression was quantified by RT-qPCR and normalized to β-Actin 
expression (pSuper was set at 1). 
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Figure 3. In vivo knock-down of Abcc2 and quantification of siAbcc2. (A) Relative Abcc2 expression was quantified by RT-qPCR 
and normalized to β-Actin (shScr group was set at 100%). (B) Relative expression of siAbcc22 and siAbcc28 molecules was 
quantified by RT-qPCR and normalized to β-Actin expression (the highest value was set at 100%). 
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Figure 4. Overexpression of shAbcc2 induces liver toxicity. (A) Alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) levels in plasma at 8-days p.i. (B) Relative expression of three cellular miRNAs, miR-122, miR-29a and let-7a was quantified 
by RT-qPCR and normalized to β-Actin expression (PBS group was set at 100%).  
 
 
 
It has been reported that high siRNA expression from 
shRNA cassettes containing a strong promoter can lead to 
lethal toxicity by over-saturating the RNAi machinery and 
affecting endogenous miRNA processing (Grimm et al, 
2006). We determined the expression levels of 3 cellular 
miRNAs, namely miR-122, miR-29a and let-7a, in the 
livers of the injected animals. If saturation of the RNAi 
machinery occurred to the point where endogenous 
metabolic processes are expected to be significantly 
affected, expression of these liver miRNAs should be 
significantly decreased. Taqman assays for the 3 cellular 
miRNAs revealed  down-regulation in the mouse livers 
injected with AAV-shScr, AAV-shAbcc22 and AAV-
shAbcc28 compared to the PBS group (Figure  4B), 
indicating oversaturation of the RNAi machinery.  
 
Circumventing shRNA toxicity  
Expression of shRNA from a weaker promoter and from a 
miRNA scaffold can circumvent toxicity problems 
(McBride et al, 2008). Therefore, shAbcc11 and shAbcc28 
sequences were expressed from a miRNA backbone 
(Figure 5A and 5B) and their ability to knock-down Luc-
Abcc11 and Luc-Abcc28 luciferase reporters was assessed 
in vitro in HEK293T cells. Comparison of knock-down 
induced by shAbcc11 and miAbcc11, and by shAbcc28 
and miAbcc28 showed that both constructs had a similar 
efficiency – the miRNA being slightly better (Figure 5C 
and 5D). Furthermore, quantification of the amount of 
siRNA molecules necessary to achieve this knock-down 
effect by Taqman assay showed that miAbcc28 produced 
55%-75% less siAbcc28 molecules than shAbcc28 (Figure 
5E). Since these miRNAs were expressed from a 
significantly weaker Pol II promoter, less siRNA 
molecules were apparently being produced while retaining 
equal inhibitory properties compared to the shRNA. This 
indicates that miRNAs may be more potent molecules for 
induction of RNA silencing than shRNAs. Considering the 
toxicity issues raised in this study the possibility of 
expressing siRNA sequences from a miRNA backbone, 
which  would  render  similar or  increased  efficiency  but  441 
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Figure 5. Expression of shAbcc11 and shAbcc28 from a miRNA scaffold and siRNA quantification. Predicted stem-loop structure 
with guide strand in red of (A) miAbcc11 and (B) miAbcc28. Luc-Abcc1 knock-down by Abcc1-targeting (C) and Luc-Abcc2 knock-
down by Abcc2-targeting (D) shRNAs and miRNAs (shScr and miScr were set at 100%). (E) Relative amount of siRNA molecules 
produced by shRNA and miRNA constructs (the lowest shRNA dose was set at 100%). 
 
 
 
 
would present reduced toxicity risks in in vivo studies is of 
considerable interest. We are currently comparing the 
long-term efficacy and toxicity profile of siRNAs 
expressed from AAV-shRNA and AAV-miRNA backbone 
in vivo. Future research will therefore focus on expressing 
siRNA from a miRNA backbone to achieve efficient and 
safe in vivo target knock-down. 
 
To our knowledge, this is the first report to show AAV-
mediated knock-down of Abcc2  in vivo. Concomitant 
toxicity was observed and was attributed to a previously 
described mechanism of oversaturation of the RNAi 
machinery (Grimm et al, 2006). Subsequent generation 
of miRNAs showed a better efficacy profile, i.e., the 
same effect mediated by significantly less siRNA 
molecules. We therefore expect that these constructs will 
yield a strong and safe knock-down following liver 
transduction with AAV. 
 
CONCLUSIONS 
 
• Expression of multiple anti-Abcc1 and anti-Abcc2 shRNAs 
• In vitro studies are insufficient predictors of the shRNAs 
processing in vivo 
• Strong knock-down of Abcc2  in vivo following AAV-
shAbcc delivery 
• Concomitant toxicity due to oversaturation of the RNAi 
machinery 
• Toxicity can be circumvented by siRNA expression from a 
natural miRNA scaffold 
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LIST OF ABBREVIATIONS 
 
gc; Genomic copies 
p.i.; Post injection 
PBS; Phosphate-buffered saline 
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